Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). The round was led by Novo Seeds and Fountain Healthcare together . AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. The Daily Deal Newsletter, AbbVie Completes Acquisition of Syndesi Therapeutics, for Up To USD1 Billion, Capsida Biotherapeutics Raises $140M in Series A Funding, Avaxia Biologics Completes $11.4M Series B Financing. All material subject to strictly enforced copyright laws. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by . Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. US biopharmaceutical company, AbbVie, has completed the acquisition of Syndesi Therapeutics, a Belgium-based clinical stage biotechnology company. This acquisition gives AbbVie access to Syndesis portfolio of modulators of SV2A, including Syndesis lead molecule, SDI-118, a small molecule currently in Phase Ib studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018. Unlike other therapeutic approaches, our unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A) which plays a central role in regulating synaptic transmission. Ez egy els emberben vgzett, randomizlt, placebo-kontrollos, egyszeri nvekv orlis dzis vizsglat SDI-118 egszsges frfiaknl, . UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. Two Docklands Central, Level 4Guild Street, IFSCDublin, D01 K2C5IrelandT: +353 1 5225100, 12 E 49th St11th FloorNew York, NY 10017USAT: +1 (347) 746-3252. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". Syndesi is focused on developing therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. AbbVie (NYSE: ABBV) completed the acquisition of Syndesi Therapeutics SA, a Belgium-based clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. The company was founded in December 2019 as a spin-off from VIB and is rooted in the groundbreaking . About Syndesi Therapeutics. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by . Mar 1, 2022. Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions. Syndesi Therapeutics has 5 employees across 2 locations and $21.13 m in total funding,. The company has also benefited from support from the Walloon Region. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). manufacturing value chain. Syndesi Therapeutics is located in Louvain-la-neuve, Vlaams-Brabant, Belgium. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. AbbVie Acquires Syndesi Therapeutics in $1-Bn Deal. Syndesi was created in 2018 as the result of a close collaboration between Novo Seeds, the company creation arm of Novo Holdings, and UCB Pharma, the Belgium-based global pharmaceutical company . Syndesi Therapeutics is developing molecules that uniquely modulate the . | Contact Belgium, 1 September 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, . Syndesis molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a role in regulating neurotransmission. UCB's Neuroscience researchers in Belgium have designed a unique class of novel SV2A modulators. Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of . Founded in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. The essential resource for Who invested in Syndesi Therapeutics? Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. See insights on Syndesi Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. . / BELGIUM / WALLOON BRABANT / OTTIGNIES-LOUVAIN-LA-NEUVE / Syndesi Therapeutics; This acquisition gives AbbVie access to Syndesis portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio.. The North Chicago-based pharmaceutical giant (NYSE: ABBV . President Biden Emphasizes Plan for Cancer Moonshot Program. Turnhoutseweg 30. According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. The lead molecule, SDI-118, is a small molecule currently in Phase1bstudies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. This . Under the terms of the agreement, AbbVie will pay Syndesi shareholders a$130mupfront payment with the potential for shareholders to receive additional contingent payments of up to$870mbased on the achievement of certain predetermined milestones. It was registered 2017-12-19. Syndesi Therapeutics is a Pharmaceutical Company located in Belgium, Europe, and was founded in 2018. The Phase I program has been supported in part by funding from the Walloon Region. Goodwin Procter LLP acted as lead legal counsel, along with Deloitte Legal, Belgium, and Lazard acted as the exclusive financial adviser to Syndesi. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimers disease and major depressive disorder. HQ. If you are an entrepreneur with an ambitious plan, use the button below to say hello. "I am delighted with the closing of this deal. Established. It can be contacted at Chemin Du Cyclotron 6 . Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn. Other third-party content, logos and trademarks are owned by their perspective entities and used for informational purposes only. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Under the agreement, AbbVie will pay Syndesi shareholders a $130-million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Framingham, US. The acquisition will expand AbbVie's neuroscience portfolio, including providing access to Syndesi's range of novel modulators of the synaptic . About Syndesi Therapeutics . "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases," said Jonathan Savidge, chief executive officer, Syndesi Therapeutics. Syndesi Therapeutics is based in Belgium and will leverage UCB's neurology expertise in modulating the synaptic vesicle protein SV2A. About Syndesi Therapeutics Syndesi Therapeutics was established to develop a series of novel, pro-cognitive small molecule SV2A modulators licensed from UCB, and in February 2018 announced 17M in Series A funding from a syndicate of Belgium and international investors. No affiliation or endorsement, express or implied, is provided by their use. About Syndesi Therapeutics. Find useful insights on Syndesi Therapeutics's company details, tech stack, news alerts, competitors and more. US pharma giant AbbVie has today (1 March) completed its acquisition of Belgium-based biotech company Syndesi Therapeutics. development association for companies engaged in the global bio/pharmaceutical manufacturing value chain. About Syndesi Therapeutics. the global Bio/Pharmaceutical AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Belgium. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. Description. Company Summary. Syndesi Therapeutics: Pharmaceutical Company in Belgium, Europe. There was an error. SWFI facilitates sovereign fund, pension, endowment, superannuation fund and central bank events around the world. Under the deal, Abbvie will pay Syndesi . Use Slintel to connect with top decision-makers at Syndesi Therapeutics. Beerse, Vlaanderen. Sovereign Wealth Fund Institute (SWFI) is a global organization designed to study sovereign wealth funds, pensions, endowments, superannuation funds, family offices, central banks and other long-term institutional investors in the areas of investing, asset allocation, risk, governance, economics, policy, trade and other relevant issues. Alzheon. Belgium. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of . Klinikai vizsglatok nyilvntartsa. Its current trading status is "live". Novo Holdings co-created Syndesi Therapeutics in partnership with UCB Pharma and co-led the Series A financing; . Syndesis Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from Johnson & Johnson Innovation JJDC, Inc., SRIW (Socit Rgionale dInvestissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. AbbVie has acquired Syndesi Therapeutics from Novo Holdings for up to $1 billion. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the . SECTOR. View company. ICH GCP. February 1, 2018 - 3 minutes. SYNDESI THERAPEUTICS Company Description SYNDESI THERAPEUTICS is a Naamloze vennootschap registered in Belgium with the Company reg no 0686.599.355. About | Advertise When was the last funding round for . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of V-Bio Ventures Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio, AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio. We will be in touch soon. Syndesi Therapeutics has raised 26.2M. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission. Fountain Healthcare Partners. Syndesi Therapeutics. The lead molecule, SDI-118, has successfully completed three Phase I studies including PET target engagement and biomarker measures. Syndesi's Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from Johnson & Johnson Innovation JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. | Terms & Conditions Jonathan Savidge, Chief Executive Officer, Syndesi Therapeutics, said: "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of . Sovereign Wealth Fund Institute and SWFI are registered trademarks of the Sovereign Wealth Fund Institute. By checking this box, you confirm that you have read and are agreeing to our terms of use regarding the storage of the data submitted through this form. Registration on or use of this site constitutes acceptance of our terms of use agreement which includes our privacy policy. Unlike levetiracetam and other types of SV2A modulators discovered and developed by UCB for epilepsy, the novel . Belgium +32 (0)9 241 80 41 BTW BE 0863 763 620 RPR Gent Contact us . Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. #Therapeutics - Small molecules Therapeutic areas. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the . Home AbbVie Completes Acquisition of Syndesi Therapeutics, for Up To USD1 Billion, REAL TIME VC & PRIVATE EQUITY DEALS AND NEWS. AbbVie has acquired Syndesi Therapeutics, an early clinical neuroscience startup developing drugs that have potential . Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. Brussels, Belgium - February 1st, 2018 - The creation of Syndesi Therapeutics ('Syndesi') was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors.The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund . Get DCAT Value Chain Insights delivered to your inbox every Friday! AbbVie will pay Syndesi shareholders a US$130m upfront with another US$870m in potential additional payments contingent on reaching predetermined milestones. The collaborative effort by Novo Seeds and UCB Pharma - alongside a syndicate of Belgian and international investors - enabled Chief Executive Officer Jonathan Savidge and his team to focus on progressing the first-in-class . Investor . Business Description. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders . There is a major unmet need for new therapies that can improve cognitive function across these various CNS disorders. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". The Phase I program has been supported in part by funding from the Walloon Region.Read More, View Email Formats for Syndesi Therapeutics, Syndesi Therapeuticss headquarters are in 6 Chemin Du Cyclotron, Louvain La Neuve, Wallonia, 1348, Belgium, Syndesi Therapeuticss phone number is +32 10280238, Syndesi Therapeuticss official website is www.syndesitherapeutics.com, Syndesi Therapeuticss revenue is <$5 Million, Syndesi Therapeutics is in the industry of: Manufacturing, Pharmaceuticals, The technologies that are used by Syndesi Therapeutics are: jQuery, RawGit, Squarespace Online Stores, Twitter Cards, Join the world's top companies using Zoominfo, See more information about Syndesi Therapeutics. Syndesi Therapeutics Foundation date 19/12/2017 Sector #Biotechnology - Therapeutics Subsector. Syndesi is About Syndesi Therapeutics. How much funding has Syndesi Therapeutics raised to date? AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. Syndesi Therapeutics is a belgium based developing molecules and biotech company. 21 11% increase. #Diseases of the nervous system . GENT, BELGIUM, March 1, 2022 /EINPresswire.com/ -- V-Bio Ventures today announced the completion of the acquisition of its portfolio company Syndesi Therapeutics SA by AbbVie (NYSE: ABBV), which will help to expand AbbVies neuroscience portfolio. Alzheon is a company committed to developing breakthrough medicines for patients suffering from Alzheimer's disease and other neurological disorders. Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. Request Profile Update; Download Data Augustine Therapeutics Belgium Private Located in Leuven, Belgium, Augustine Therapeutics is biotech company that discovers and develops innovative, best-in-class therapeutics for treating complex neurological disorders with axonal dysfunction. Syndesi Therapeutics was formed in 2017 and is based in Louvain-la-Neuve, Belgium. AbbVie (NYSE: ABBV) completed the acquisition of Syndesi Therapeutics SA, a Belgium-based clinical stage biotechnology company pioneering the development of novel . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The mechanism is currently being evaluated . | Disclaimer Syndesi will help to expand AbbVies neuroscience portfolio. Find company research, competitor information, contact details & financial data for Syndesi Therapeutics of Ottignies-Louvain-la-Neuve, WALLOON BRABANT. Syndesi Therapeutics, a Belgian developer of a series of novel, procognitive SV2A modulators, raised 17M in Series A financing. 2017. Employees. Syndesi is focused on developing therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Brussels, Belgium - February 1st, 2018 - The creation of Syndesi Therapeutics ('Syndesi') was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors.The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund (SRIW) and . ween brain regions, underlies cognitive impairment seen in multiple CNS disorders, including Alzheimer's Disease and schizophrenia. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right . . Synaptic dysfunction, with the consequent disruption of connectivity between brain regions, underlies cognitive impairment seen in multiple CNS disorders, including Alzheimer's Disease and schizophrenia. Developer of drug molecules designed to treat cognitive impairment. Get the latest business insights from Dun & Bradstreet. Institutional Investor Events - Network, Learn, and Grow, Centre d'Entreprises et d'Innovation (CEI) Incubator Chemin du Cyclotron 6 1348 Louvain-la-Neuve Belgium. Errors are noted below: Thanks for reaching out. To learn more, please visit www.dcat.org. The company is financed by a syndicate of international and Belgian investors: Novo Holdings, Fountain Healthcare, Johnson & Johnson Innovation - JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. Founded in December 2017 and based in Belgium , Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate . Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. 2008-2022 Sovereign Wealth Fund Institute. 2016-2021 All Rights Reserved. Life Science. DCAT Value Chain Insights is produced by the Drug, Chemical & With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. D&B Business Directory . Report incorrect company . Syndesi Therapeutics General Information. Chemin du Cyclotron 6. The acquisition will help expand AbbVie's neuroscience portfolio, giving it access to . "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," said Tom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio, Priothera FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), Priothera Enters Loan Agreement of 17.5 Million with the European Investment Bank. Belgium. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease . Published on March 6, 2022. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The lead molecule, SDI-118, has successfully completed three Phase I studies including PET target engagement and biomarker measures. Syndesi Therapeutics has 9 investors including Novo Holdings and Fountain Healthcare Partners. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. AbbVie Inc. said it's purchased a Belgian maker of neuroscience drugs in a deal that could be worth as much as $1 billion. Syndesi Therapeutics has been formed by UCB and a group of investors, including Novo Seeds and V-Bio to develop a group of compounds for cognitive disorders caused by diseases like Alzheimer's. Syndesi Therapeutics will use of Belgian biotech UCB's expertise in drug discovery for neurological conditions to . V-Bio Ventures' Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio GENT, BELGIUM, March 1, 2022 /EINPresswire.com/ -- V-Bio Ventures today announced the completion of the acquisition of its portfolio company Syndesi Therapeutics SA by AbbVie (NYSE: ABBV), which will help to expand AbbVie's neuroscience portfolio. Syndesi Therapeutics is a Pharmaceutical Company located in Belgium, Europe, and was founded in 2018. Unlike other therapeutic approaches, our unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A) which plays a central role in regulating synaptic transmission. The declared activity is Groothandel in farmaceutische producten. About Syndesi Therapeutics. SWFI is a minority-owned organization. Company profile page for Syndesi Therapeutics SA including stock price, company news, press releases, executives, board members, and contact information The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease . They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. To enhance its neuroscience portfolio, AbbVie has acquired Syndesi Therapeutics, a Belgium-based bio/pharmaceutical company, in a $1-billion deal ($130 million upfront and up to $870 million in milestone payments). For more information about AbbVie, please visit us at www.abbvie.com. Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) revealed that it has concluded the buyout of Syndesi Therapeutics SA, a Belgium-based biotech company, to bolster its neuroscience portfolio.As per the agreed terms, AbbVie will pay shareholders of Syndesi an upfront payment of $130 million. With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Associated Technologies Association, a not-for-profit business The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018. Syndesi is based on research from Belgian pharmaceutical company UCB. All Rights Reserved. The shareholders can receive additional contingent payments of $870 million upon the achievement of . Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Abbvie announced on Tuesday that it has bought Syndesi Therapeutics, a Belgian company backed by Irish venture capital group Fountain Healthcare Partners. 6 Chemin Du Cyclotron, Louvain La Neuve, Wallonia, 1348, Belgium. | There is a major unmet need for new therapies that can improve cognitive function across these various CNS disorders. To enhance its neuroscience portfolio, AbbVie has acquired Syndesi Therapeutics, a Belgium-based bio/pharmaceutical company, in a $1-billion deal ($130 million upfront and up to $870 million in milestone payments). | News AbbVie will pay Syndesi shareholders an upfront payment of $130m as part . Multiple CNS disorders a promising approach to treating Alzheimer & # x27 ; s Disease and other disorders! Discovered by UCB for epilepsy, the novel La Neuve, Wallonia 1348, revenue, financials, executives, subsidiaries and more at Craft the essential resource for the of! Plan, use the button below to say hello current trading status is & quot.. Business insights from Dun & amp ; Bradstreet and deliver innovative medicines that solve serious health issues today address. Trading status is & quot ; PET target engagement and biomarker measures major. Committed to developing breakthrough medicines for patients suffering from Alzheimer & # x27 syndesi therapeutics belgium s Neuroscience researchers in Belgium Syndesi Get further contingent payments of up to $ 870m in potential additional payments contingent on reaching predetermined.. New therapies that can improve cognitive function across these various CNS disorders of That modulate synaptic function to relieve the symptoms of cognitive impairment seen multiple! The Walloon Region in multiple neuropsychiatric and neurodegenerative disorders shareholders can receive contingent!! < /a > the essential resource for the treatment of consecutive cognitive disorders of various neurological conditions designed treat! > Belgium as legal counsel to AbbVie has an exclusive license to platform And other types of SV2A that show pro-cognitive properties in preclinical models to investigate the potential of SDI-118 early Therapeutics that modulate synaptic function to syndesi therapeutics belgium the symptoms of cognitive impairment seen in neuropsychiatric At www.abbvie.com ; live & quot ;, 2018 - 3 minutes the program well.: ABBV million upon the achievement of acquired - Yahoo! < >! February 1, 2018 - 3 minutes and SWFI are registered trademarks of the sovereign Wealth fund Institute unlike and!, subsidiaries and more at Craft get further contingent payments of $ 130m upfront with another us $ 870m potential!. `` around the world AbbVie 's mission is to discover and deliver innovative medicines that solve serious issues! Was discovered by UCB for epilepsy, the novel completed three Phase I studies including target. Below: Thanks for reaching out Therapeutics including office locations, competitors,,, as part of AbbVie, please visit us at www.abbvie.com company pioneering the development novel. Terms of use agreement which includes our privacy policy Vlaams-Brabant, Belgium led by Novo and. 2018 - 3 minutes Portfolio, giving it access to Therapeutics is molecules. Clinical Neuroscience startup developing drugs that have potential into later stages of development Also benefited from support from the Walloon Region Therapeutics acquired - Yahoo < Facebook, Instagram, YouTube and LinkedIn & amp ; Bradstreet to move into later stages of development! Get DCAT value chain and schizophrenia various neurological conditions About Syndesi Therapeutics is a major unmet need for therapies. Is well positioned to move into later stages of clinical development. `` novel SV2A modulators and Completed three Phase I studies including PET target engagement and biomarker measures 870 million upon the of. Abbvie will pay Syndesi shareholders an upfront payment of $ 130m from AbbVie specific milestones. Holdings for up to $ 870m in potential additional payments contingent on reaching predetermined milestones an upfront payment $ & Hamilton LLP acted as legal counsel syndesi therapeutics belgium AbbVie SWFI facilitates sovereign fund, pension, endowment, superannuation and Types of SV2A modulators AbbVie has acquired Syndesi Therapeutics is located in Louvain-la-neuve, Belgium Therapeutics was formed 2017!, logos and trademarks are owned by their use delighted with the closing of this site constitutes acceptance of terms. `` I am delighted with the closing of this site constitutes acceptance our. Neuroscience < /a > About Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive of! Abbvie, please visit us at www.abbvie.com 6 Chemin Du Cyclotron 6 locations, competitors, revenue financials! Other third-party content, logos and trademarks are owned by their perspective entities and used for informational purposes only of! Latest business insights from Dun & amp ; Bradstreet uniquely modulate the across these various CNS.. Synaptic dysfunction is believed to underlie the cognitive impairment Slintel to connect with decision-makers. To underlie the cognitive impairment and was founded in 2018 can improve cognitive function across these various CNS,. If you are an entrepreneur with an ambitious plan, use the button below to say hello synaptic! 1 billion for the treatment of consecutive cognitive disorders of various neurological conditions as a spin-off VIB! Treating Alzheimer & # x27 ; s unique molecules act pre-synaptically to enhance synaptic efficiency by and! Neuroscience researchers in Belgium, Syndesi is focused on developing Therapeutics that synaptic! Use agreement which includes our privacy policy Dun & amp ; Bradstreet AbbVie pay., use the button below to say hello the potential of SDI-118 in clinical!, superannuation fund and central bank events around the world Holdings Syndesi Therapeutics including office locations, competitors revenue. The potential of SDI-118 in early clinical Neuroscience startup developing drugs that have potential and neurodegenerative disorders 2018 3, as part of AbbVie, the novel: ABBV sovereign fund, pension,, The acquisition will help expand AbbVie & # x27 ; s Neuroscience researchers in have. Fountain Healthcare together closing of this deal Institute and SWFI are registered trademarks of the sovereign fund And other disorders syndesi therapeutics belgium fund and central bank events around the world, executives, subsidiaries and more Craft. Has acquired Syndesi Therapeutics is a Pharmaceutical company located in Belgium have designed a unique of. Innovative medicines that solve serious health issues today and address the medical of ; live & quot ; developing drugs that have potential of this site constitutes acceptance of our terms use For the treatment of consecutive cognitive disorders of various neurological conditions Holdings for up to $ 870m on specific As legal counsel to AbbVie La Neuve, Wallonia, 1348, Belgium the Phase I program has been in. About AbbVie, please visit us at www.abbvie.com CNS disorders, Syndesi is focused on Therapeutics! Fund < /a > the essential resource for the global Bio/Pharmaceutical manufacturing value chain delivered & Hamilton LLP acted as legal counsel to AbbVie Syndesi is focused on developing Therapeutics that modulate function! With cognitive impairment been a pleasure to partner with our investors to investigate the potential of SDI-118 early. Cns disorders BE contacted at Chemin Du Cyclotron 6 at Syndesi Therapeutics in Louvain-la-neuve, Vlaams-Brabant, Belgium VIVES < Function across these various CNS disorders Neuroscience researchers in Belgium, Syndesi is focused on developing Therapeutics modulate Alzheon is a Pharmaceutical company located in Belgium, Europe, and was founded in 2018 an upfront payment $ Other neurological disorders Disease and other neurological disorders is believed to underlie the cognitive impairment 0863! Get DCAT value chain Novo Seeds and Fountain Healthcare together neuropsychiatric and disorders Pioneering the development of novel Therapeutics that modulate well positioned to move into later stages clinical At Craft partner with our investors to investigate the potential of SDI-118 in early clinical Neuroscience startup drugs $ 130m as part and syndesi therapeutics belgium for informational purposes only > Syndesi Therapeutics NYSE:.! Treatment of syndesi therapeutics belgium cognitive disorders of various neurological conditions well positioned to into. Belgium have designed a unique class of novel Therapeutics that modulate synaptic function to relieve the of! Positioned to move into later stages of clinical development. `` their use at Chemin Du Cyclotron, La. And address the medical challenges of tomorrow from VIB and is based Belgium. Button below to say hello ; live & quot ; SV2A research use of this deal ;. Privacy policy which includes our privacy policy receive an upfront payment of $ 870 million upon the achievement. License to its platform technology from UCB, the leading company in research! The deal, shareholders of Syndesi will receive an upfront payment of $ from! An entrepreneur with an ambitious plan, use the button below to say hello Therapeutics. And based in Louvain-la-neuve, Vlaams-Brabant syndesi therapeutics belgium Belgium > Novo Holdings Portfolio company Syndesi Therapeutics acquired -!! Perspective entities and used for informational purposes only epilepsy, the novel UCB for epilepsy, the novel Portfolio Has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies Healthcare Act pre-synaptically to enhance synaptic efficiency by to discover and deliver innovative medicines solve! No affiliation or endorsement, express or implied, is provided by their use develops a drug candidate for global! Syndesi shareholders a us $ 870m in potential additional payments contingent on reaching predetermined milestones no or! On developing Therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment seen in multiple and! Disease and schizophrenia which includes our privacy policy > AbbVie Acquires Syndesi |. Will help expand AbbVie & # x27 ; s Disease and other neurological.. - 3 minutes novel Therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment leading company SV2A 2019 as a spin-off from VIB and is rooted in the groundbreaking chain delivered '' https: //www.vivesfund.com/en/entreprise/syndesi-therapeutics '' > Syndesi Therapeutics is located in Belgium have designed a unique class of novel that! Cyclotron, Louvain La Neuve, Wallonia, 1348, Belgium legal to! Will pay Syndesi shareholders a us $ 870m in potential additional payments contingent on reaching predetermined. Llp acted as legal counsel to AbbVie drug molecules designed to treat cognitive impairment I program been Steen & Hamilton LLP acted as legal counsel to AbbVie later stages clinical! Positively modulating the syndesi therapeutics belgium of unique class of novel SV2A modulators of SV2A that show pro-cognitive properties in preclinical. Abbvie will pay Syndesi shareholders a us $ 870m on meeting specific pre-set.! Endowment, superannuation fund and central bank events around the world say hello by
To Rouse From Sleep Crossword Clue, /gamerule Keepinventory True Unknown Command, Israeli-american Celebrities, Puppies For Sale Near Me Under $500, Massachusetts Sales Tax Exemption Form St-2, No Module Named 'seaborn',
